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Abstract
Background:  DNA-protein interactions in mature brain are increasingly recognized as key
regulators for behavioral plasticity and neuronal dysfunction in chronic neuropsychiatric disease.
However, chromatin assays typically lack single cell resolution, and therefore little is known about
chromatin regulation of differentiated neuronal nuclei that reside in brain parenchyma intermingled
with various types of non-neuronal cells.
Results: Here, we describe a protocol to selectively tag neuronal nuclei from adult brain – either
by (anti-NeuN) immunolabeling or transgene-derived histone H2B-GFP fusion protein – for
subsequent fluorescence-activated sorting and chromatin immunoprecipitation (ChIP). To illustrate
an example, we compared histone H3 lysine 4 and 9 methylation marks at select gene promoters
in neuronal, non-neuronal and unsorted chromatin from mouse forebrain and human cerebral
cortex, and provide evidence for neuron-specific histone methylation signatures.
Conclusion: With the modifications detailed in this protocol, the method can be used to collect
nuclei from specific subtypes of neurons from any brain region for subsequent ChIP with native/un-
fixed or crosslinked chromatin preparations. Starting with the harvest of brain tissue, ChIP-ready
neuronal nuclei can be obtained within one day.
Background
An increasing number of neurodevelopmental and neu-
ropsychiatric disorders are thought to result from defec-
tive DNA:protein interactions specifically in neurons;
furthermore, sustained changes in neuronal gene expres-
sion and behavior after exposure to certain drugs or stim-
uli are likely to involve chromatin remodeling, including
DNA methylation and histone modification changes [1-
5]. However, even the most sensitive chromatin immuno-
precipitation assays and most other approaches used to
study the regulation of DNA and histone modifications,
transcription factor binding etc., lack single cell resolution
and instead require the preparation of homogenates from
at least 103 – 107 nuclei. Consequently, detailed chroma-
tin analysis was until now not feasible for nuclei of termi-
nally differentiated neurons that typically reside in brain
parenchyma intermingled with various types of glia and
other cells mostly in a 2:1 – 1:2 ratio, dependent on spe-
cies and brain regions [6,7].
Published: 28 April 2008
BMC Neuroscience 2008, 9:42 doi:10.1186/1471-2202-9-42
Received: 29 January 2008
Accepted: 28 April 2008
This article is available from: http://www.biomedcentral.com/1471-2202/9/42
© 2008 Jiang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2008, 9:42 http://www.biomedcentral.com/1471-2202/9/42
Page 2 of 9
(page number not for citation purposes)
Recently, immunostaining in conjunction with fluores-
cence-activated cell sorting (FACS) was used successfully
to selectively collect neuronal nuclei from human (post-
mortem) brain tissue for the purposes of retrospective
birth dating [8] or assessment of age-related changes in
DNA cytosine methylation [9]. However, these studies uti-
lized the nuclear harvest for highly sensitive radiation and
PCR assays, and it remained unclear whether the protocol
could be modified for the purposes of chromatin immu-
noprecipitation and other techniques that require com-
paratively larger amount of input (for example, 105 107
nuclei). We provide a detailed protocol for selective sort-
ing of neuronal nuclei from mouse and human brain in
quantities sufficient for immunoprecipitation with differ-
ent chromatin preparations (enzyme-based digestion and
crosslinking/sonication), followed by microarray or PCR
studies. In addition, we introduce a transgenic mouse line
for neuron-specific expression of GFP (enhanced green
fluorescent protein)-tagged histone H2B. Evidence is pre-
sented that even under baseline conditions, promoter-
bound histone methylation in neuronal samples is signif-
icantly different when compared to unsorted, or non-neu-
ronal nuclei from the same brain region. Therefore, the
methods presented here will be important for the study of
molecular mechanisms governing epigenetic control of
neuronal gene expression and chromatin remodeling spe-
cifically in mature brain.
Results
H2B-GFP transgenic mice
The promoter of the ? subunit of the Ca2+/calmodulin
dependent protein kinase II gene (CAMKII) was used to
drive H2B-EGFP expression; as expected, this transgene
labeled most of the neuronal populations in the fore- and
midbrain, including cortex, striatum, hippocampus, with
the notable exception of the GABAergic interneurons in
cerebral cortex and hippocampus (Fig. 3). In contrast,
labeling in hindbrain, incl cerebellum, was less consistent
(data not shown). The transgene-derived labeling of neu-
ronal nuclei with H2B-EGFP was robust pre- and post-
FACS (Fig. 2, panel a-d). To date, our oldest transgenic
mice are 5 months of age and so far we did not observe
any overt neurological phenotypes, even in animals
expressing the fusion protein at comparatively high levels
in CNS neurons. Likewise, no adverse effects were
reported for transgenic mice expressing high levels of
H2B-EGFP in a wide range of tissues, including brain [10].
Loss of nuclei during the procedure
Each of the major steps in this protocol – (1) extraction of
nuclei from the tissue, (2) ultracentrifugation, (3) immu-
nolabeling and (4) fluorescence-activated sorting – could
result in loss of nuclei, together totaling perhaps up to
50% of the neuronal nuclei in the starting material. How-
ever, despite of these limitations, the alternative
approach, such as nuclei harvesting from primary neuro-
nal culture, is likely not to improve results in a higher
yield and would have the additional disadvantage of any
ex vivo preparation.
Nucleosomes are preserved in sorted nuclei
Nucleosomes as the elementary unit of chromatin – are
comprised of 146 bp of genomic DNA wrapped around
core histones H2A, H2B, H3 and H4. To find out whether
Outline of the procedure to isolate neuronal nuclei from  brain for chromatin immunoprecipitation Figure 1
Outline of the procedure to isolate neuronal nuclei 
from brain for chromatin immunoprecipitation.BMC Neuroscience 2008, 9:42 http://www.biomedcentral.com/1471-2202/9/42
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nucleosomal structures remain intact in sorted NeuN+
nuclei, we compared nucleosome occupancy at promoters
in forebrain from unsorted and NeuN+ nuclei, using a
modification-independent anti-H3 C-terminus antibody
for ChIP-DSL in conjunction with M8K promoter array
(Fig 4A, B). No significant differences between chip-to-
input ratios of sorted NeuN+ and unsorted nuclei were
observed. Instead, H3 occupancy at specific promoter
sequences showed a strong correlation between the
NeuN+ and unsorted samples (Spearman rank, r =
0.651370, p < 2.2e-16) (Fig. 4B). We conclude that pro-
moter-bound nucleosomes are intact after the sorting pro-
cedure.
Differential histone H3 methylation in neuronal nuclei
To find out whether or not neuronal chromatin, under
baseline conditions, shows a histone methylation signa-
ture that is different compared to unsorted nuclei, we con-
ducted ChIP for two histone lysine methylation marks,
H3K4me2 and H3K9me3. All studies were conducted on
the forebrain of male mice 8–12 weeks of age. Histone
methylation levels were at 3 out of 4 – arbitrarily chosen
– gene promoters significantly different in neuronal chro-
matin (Fig. 4C). Furthermore, in 2 out of 4 promoters
(B2m, Mecp2), changes in the "open" mark, H3K4me2
and the "repressive" mark, H3K9me3, were in the oppo-
site direction (Fig. 4C). Notably, H3K9me3 levels at the
Mecp2 promoter – i.e., the Rett syndrome gene which is
robustly and ubiquitously expressed in mature CNS neu-
rons [11-15] – were higher in neuronal vs. unsorted chro-
matin. This particular finding was unexpected and
requires further investigations.
Next, we wanted to (i) find out whether the above find-
ings can be extrapolated to species other than mouse and
(ii) further confirm that histone lysine methylation at
select gene loci is differentially regulated in neurons as
compared to non-neuronal cells residing in the same tis-
sue. To this end, we utilized postmortem tissue from the
human prefrontal cortex for ChIP with H3-tri-methyl-
lysine 4 (H3K4me3), a chromatin mark enriched at sites
Neuronal nuclei isolated from adult brain via FACS Figure 2
Neuronal nuclei isolated from adult brain via FACS. 
(A) Digitized images of nuclei extracted from forebrain of 
adult (a-d) CAMIIK-H2B-GFP transgenic mice, and (e-j) wild 
type mice labeled with NeuN immunoreactivity, as indicated 
pre and post (FACS sorting), and after pelleting. Green chan-
nel for (a, c) GFP or (e, g, i) NeuN; blue channel for DAPI. 
Notice that post-FACS samples are comprised entirely of 
neuronal nuclei. Bar = 20 μm. (B) Representative FACS scat-
ter plots from (a) negative control (NC) processed without 
NeuN antibody, and (b) sample processed with NeuN anti-
body (NeuN).
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Neurons expressing H2B-GFP transgene Figure 3
Neurons expressing H2B-GFP transgene. Digitized 
images from 8 week old CAMIIK-H2B-GFP mice. (a) Cere-
bral cortex. Notice GFP (green) nuclei across layers II-VI, but 
not in layer I or white matter (WM). (b) caudate-putamen 
and (c) hippocampus. (d-f) Nuclei extracted from forebrain 
and processed for NeuN (red), and nucleophilic dye, DAPI 
(blue). Notice that GFP (green) expression is limited to 5 of 
the 6 NeuN immunoreactive nuclei. Arrows label GFP-, 
NeuN- nuclei, * labels GFP-, NeuN+ nucleus. (g) Section 
from cerebral cortex labeled with anti-GAD67 antibody 
(red). Notice absence of GFP signal in GABA neuron. Bar is 
(a, c) 100, (b) 300, (d-g) 5 μm.
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of active gene expression [16,17]. For each tissue sample,
NeuN immunopositive and immunonegative nuclei were
sorted separately by FACS, and then processed in parallel
for anti-H3K4me3 ChIP followed by qPCR for the follow-
ing genes: (1) The subunit 2B of the NMDA receptor
(GRIN2B) and (2) brain-derived neurotrophic factor
(BDNF); both these genes are in postnatal and adult brain
predominantly or exclusively expressed in neurons
[18,19]. (3) ? 2 microglobulin (B2M), which in CNS is
expressed in a mixed population of neuronal and non-
neuronal cells and considered as a "housekeeping gene"
in postmortem studies [20,21], and (4) the locus control
region of the ? globin locus (HBB), which is highly regu-
lated in erythopoetic tissues but silent and inactive in
brain [22,23]. Levels of H3K4me3 at promoters of the
neuron-specific genes, GRIN2B and BDNF, were consist-
ently higher in chromatin of the NeuN+ nuclei as com-
pared to NeuN- (Fig. 5). These changes were highly
specific because H3K4me3 levels in chromatin surround-
ing B2M were higher in NeuN- nuclei, and furthermore,
H3K4me3 at the HBB locus control region were overall
very low (Fig. 5). Taken together, our findings in mouse
Neuron-specific chromatin signatures in human prefrontal  cortex Figure 5
Neuron-specific chromatin signatures in human pre-
frontal cortex. Bar graphs showing ChIP-to-input ratio (y-
axis) for trimethylated H3-lysine 4 (H3K4me3) at GRIN2B, 
BDNF and B2M promoters, and HBB (?-globin) locus control 
region in chromatin of NeuN positive (NeuN+) and negative 
(NeuN-) FACS sorted nuclei from human prefrontal cortex. 
Data shown as mean ± S.E.M., N = 3 specimens/sorting. The 
NeuN+ fraction showed, in comparison to NeuN- fraction of 
the same subject, increased levels of H3K4me3 at GRIN2B 
and BDNF in 3/3 cases. Notice further the extremely low 
ChIP-to-input ratio for HBB.
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Neuron-specific chromatin signatures in mouse brain Figure 4
Neuron-specific chromatin signatures in mouse brain. (A) Representative gel picture for 25 cycle PCR product (ChIP-
GLAS) from 4 independent replicates of Input I and ChIP C, and water control W. (B) Scatter plot showing correlation 
between Chip-to-input ratios signal from NeuN+ sorted nuclei (NeuN+ FACS) (x-axis) and unsorted nuclei (NON-FACS) (y-
axis), using modification-independent antibody against C-terminus of histone H3 anti-H3. (C) Bar graphs showing ChIP-to-input 
ratio (y-axis) for (top row) dimethylated H3-lysine 4 (H3K4me2) and (bottom row) trimethylated H3-lysine 9 (H3K9me3) as 
determined for Mecp2, Gad1, B2m, and Gfap gene promoters in chromatin of NeuN+ FACS and NON-FACS nuclei from 
mouse forebrain. Data shown as mean ± S.E.M., N = 6/sorting; *p < 0.05, ANOVA NeuN+ FACS v.s. NON-FACS.
0
4
8
H
3
K
4
m
e
2
C
h
I
P
/
I
n
p
u
t
B2m
*
NeuN+ FACS
NON-FACS
0.00
0.01
0.02
0.03
H
3
K
9
m
e
3
C
h
I
P
/
I
n
p
u
t
*
Mecp2
0.00
0.04
0.08
0.12
*
Gfap
0.00
0.02
0.04
0.0
0.2
0.4
0.0
0.4
0.8
1.2 *
Gad1
0.00
0.01
0.02
0.03
*
C A
B
ICICICICW
bp
200
300
100
N
O
N
-
F
A
C
S
 
 
NeuN+ FACS
anti-H3
log2(ChIP/Input)
 
 
 
l
o
g
2
(
C
h
I
P
/
I
n
p
u
t
)
-5
0
5
-5 0 5
0.0
0.8
1.6
NeuN+ FACS
NON-FACS
NeuN+ FACS
NON-FACS
NeuN+ FACS
NON-FACSBMC Neuroscience 2008, 9:42 http://www.biomedcentral.com/1471-2202/9/42
Page 5 of 9
(page number not for citation purposes)
forebrain and human prefrontal cortex suggest that – even
at baseline – important differences exist between histone
methylation signatures of neuronal and non-neuronal
chromatin.
Conclusion
The protocol presented here should be particularly useful
to investigators who wish to study chromatin regulation,
including epigenetic mechanisms of neuronal gene
expression, in the mature and the aging brain. The alterna-
tive approach, i.e. the study of primary neuronal cultures
or neuron-like cell lines, certainly is suited to model
developmental mechanisms and neurodevelopmental
disease [24-29]. However, neurons and other CNS cells
are sustainable in culture, at best, for a few weeks [30,31]
and therefore are not ideal from the viewpoint of chronic
neuropsychiatric diseases, which often involve a pro-
tracted course, late onset and predilection for a specific
neuronal subtype. Furthermore, the complexities of brain
connectivity and circuitry, among a myriad of other fac-
tors, is difficult or impossible to model ex vivo. For exam-
ple, in vivo treatment with antipsychotic drugs induces
chromatin remodeling in cerebral cortex and striatum, an
effect that cannot be mimicked in cortical or striatal cell
cultures lacking input from monoamine pathways [32-
34]. Finally, chromatin assays in whole brain tissue are
potentially confounded by cellular heterogeneity, includ-
ing potential shifts in cellular composition during the
course of aging or due to disease. Given that chromatin
immunoprecipitation with genome-wide coverage from
as little as 10,000 cells is now feasible [35], it should be
possible to use transgenic mice – including the CAMIIK-
H2B-GFP lines presented here – to selectively study the
epigenome for highly defined subpopulations of neurons
in the mouse. Furthermore, the relative resilience of nuclei
in frozen-then-thawed postmortem brain tissue makes it
possible to apply the techniques presented here to species
other than small laboratory animals, including normal
and diseased human brain. It remains to be determined
whether or not the approach presented here is applicable
to tissues other than brain. When compared to sorting
protocols that are based on trypsinization of tissue and
sorting of intact (neuronal or non-neuronal) somata [36],
our approach has several advantages. First, it is applicable
to frozen tissues. Second, the yield of recovered nuclei
appears to be much higher, albeit direct comparisons are
lacking. Third, it is comparatively simple as compared to
related protocols.
To summarize, the perspective to develop chromatin
assays for specific types of neuronal populations of the
mature brain, as described here, will be relevant for a wide
range of physiological and neurological conditions
related to transcriptional regulation and chromatin
remodeling.
Methods
An overview of the procedure is provided in Fig. 1
Human
Procedures involving human postmortem brain were
approved by the institutional review boards of the Univer-
sity of Massachusetts Medical School. Frozen tissues (pre-
frontal cortex) from 3 specimens (age range: 8–69 years,
autolysis interval 5–28 hours) were obtained from the
Brain and Tissue Banks for Developmental Disorders,
University of Maryland (National Institute of Child
Health and Human Development Contract NO1-HD-8-
3284) and from a brain bank at the University of Califor-
nia at Davis (Center for Neuroscience, Director Dr.
Edward G. Jones).
Mice
A cassette, comprised of 8 kB of the CamIIK (? subunit)
promoter and 1.4 kB of histone H2b-eGFP cDNA (CaMK
II-H2B-EGFP), was used to generate 3 lines of transgenic
mice by pronuclear injection. All the experiments were
performed in strict accordance with Institutional Guide-
lines regarding use of experimental animals.
Reagents and reagent setup
Chemicals used include the following: 1 × PBS (Cellgro,
21-040-CV), Triton X-100 (Fluka, 93426), Igepal CA-630
(NP-40) (Sigma, 1–3021), Protease inhibitor cocktail tab-
lets (Roche, 11697498001), Phenylmethanesulfonyl Flu-
oride (PMSF) (Sigma, P7626), Mouse anti-NeuN
(Upstate, MAB377), Goat anti-mouse IgG, Alexa Fluor
488 (Invitrogen, A11029), Bovine serum Albumin (BSA)
(Sigma, B-4287), Normal goat serum (Vector, S-1000),
Micrococcal nuclease (Sigma, N-3765), Protein G Agar-
ose, (Upstate, 16–266), Rabbit Anti-H3 (Abcam,
ab1791), Rabbit Anti-H3K4me2 (Upstate, 07–030), Rab-
bit Anti-H3K9me3 (Upstate, 07–442), Rabbit Anti-
H3K4me3 (Upstate, 07–473), Normal rabbit IgG
(Upstate, 120370)
Nuclei Extraction Buffer (NEB): 0.32 M Sucrose, 5 mM
CaCl2, 3 mM Mg(Ac)2, 0.1 mM EDTA, 10 mM Tris-HCl
(pH8), 1 X Protease inhibitor cocktail, 0.1 mM PMSF, w/
o 0.1% Triton X-100, w/o 0.1% NP-40. Sucrose Cushion:
1.8 M Sucrose, 3 mM Mg(Ac)2, 10 mM Tris-HCl (pH8).
Blocking Solution: 0.5%. Bovine serum albumin (BSA),
10% normal goat serum, in 1 × PBS.
Nuclei extraction from brain tissue
Total nuclei were extracted via sucrose gradient ultracen-
trifugation. In the work presented here (mouse), each
sample was derived from a single forebrain (adult males,
8–12 weeks of age); (human) 1000 mg of cerebral cortex.
All the reagents used were pre-chilled and the entire pro-
cedure was performed on ice. Fresh or frozen samples
were homogenized by douncing 50 times in 5 mL NEBBMC Neuroscience 2008, 9:42 http://www.biomedcentral.com/1471-2202/9/42
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with 0.1% Triton X-100, or alternatively, 0.1% NP-40. Tri-
ton X-100 was preferable if nuclei require immunotagging
(with NeuN, for example), while NP-40 as a milder deter-
gent left more nuclei intact and sufficient when working
with nuclei expressing GFP. After douncing, brain
homogenates were transferred into 14 mL ultracentrifuge
tubes (Beckman, 14 × 95 mm, 344061), and 9 mL of
Sucrose Cushion was carefully loaded directly to the bot-
tom of the ultracentrifuge tube. Ultracentrifugation was
performed at 24400 rpm for 2.5 hrs at 4°C (Beckman, L8-
70M, SW28 rotor). After centrifugation, a nuclei pellet –
thin and typically with a light yellow taint – was formed
on the bottom of the tube. The sticky white tissue debris
was restrained in the middle interface of the two sucrose
layers. Supernatant, including debris, was carefully
removed. 1200 µl of chilled 1 × PBS was then added into
the tube and incubated without disturbing the pellet, for
20 min on ice. This incubation is recommended because
the nuclei pellet is easier to dissociate and consequently,
there will be less damage to the nuclei. After incubation,
the nuclei were dissociated by pipetting up and down.
FACS required single nuclei in solution but excess pipet-
ting tended to break nuclei, at least in the unfixed prepa-
rations. Pipetting required optimization by checking the
nuclei "quality" (intact single nuclei, non-adhering, with-
out debris) under the light microscope. The total number
of nuclei was counted by using a hemacytometer. One
mouse forebrain typically yielded 20–30 × 106 unfixed
nuclei after ultracentrifugation.
One alternative option was to fix the nuclei by directly
douncing the tissue in NEB containing 1% formalin. Typ-
ically, we fixed with formalin at room temperature for 5–
10 min, and then added glycine to a final concentration of
125 mM. The fixed nuclei were pelleted by centrifugation,
re-suspended in 5 mL of NEB, and subjected to ultracen-
trifugation as described above. Nuclei clumping during
isolation was – in our experience – usually to blame if the
final yield was lower than expected. For unfixed samples,
factors that appear to promote clumping are (i) contami-
nation from brain debris, or (ii) DNA leaking from bro-
ken nuclei, which appears to be alleviated via careful
handling and performing the whole procedure on ice.
When a fixation step was included (see above), the only
way to significantly alleviate the clumping was to remove
Ca2+ from the NEB, albeit this increased the proportion of
broken and damaged nuclei. Thus, lower post-FACS yield
is to be expected when working with fixed samples.
Immunotagging of neuronal nuclei
Next, neuronal nuclei were tagged by immnofluorescence
staining, using an anti-NeuN antibody (Fig. 2A, panels e-
j). Firstly, anti-NeuN (Ms) and anti-Ms IgG (Alexa 488)
antibodies were co-incubated at room temperature for 5
min (Table 1), then nuclei solution was added and the
mixture incubated in darkness for at least 20 min at 4°C
before FACS. The proportion of NeuN positive nuclei in
the material recovered after ultracentrifugation was about
50%. The FACS background signal was minimal in these
preparations (Fig. 2B, panel a).
Neuronal nuclei isolation via FACS
Next, the fluorescent nuclei (H2B-GFP transgene or NeuN
labeled) were filtered through a 40 µm Nitex mesh to
remove any remaining clumps, and then run through a
FACS machine (Vantage SE/Diva, BD Biosciences) with
proper gates settings based on the size and density of
nuclei, to ensure that only single NeuN+ nuclei were
sorted, which typically included 40% of the whole popu-
lation (Fig. 2B, panel b). After FACS, the NeuN+ nuclei
were reanalyzed to confirm the purity. Sample purity typ-
ically is > 95%. For selected samples, the purity of NeuN+
nuclei was checked under the microscope (Fig. 2A, panels
c, d and g, h). FACS sorting should be performed on the
same day as extraction and NeuN labeling of nuclei. For a
subset of experiments, including those involving human
postmortem brain, immunonegative (NeuN-) nuclei were
collected and processed in parallel to the fraction of neu-
ronal (NeuN+) nuclei.
Expected yield of neuronal nuclei
We usually obtained – from a single mouse forebrain –
2.5 × 106 NeuN+ nuclei post-FACS if fixative was added to
the NEB and up to 8 × 106 nuclei if processed unfixed. We
usually obtained from 1000 mg of human (prefrontal)
cerebral cortex 5 × 106 NeuN+ nuclei if processed unfixed.
Post-FACS nuclei pelleting
After FACS, nuclei were collected in a large volume of 1 ×
PBS, roughly 4 × 106 nuclei in 10 mL of 1 × PBS. This was
not ideal for ChIP because processing such a large volume
is associated with very high expense and potential "wast-
Table 1: Antibodies used for immunotagging of neuronal nuclei.
Primary/secondary antibody conjugate
anti-NeuN (Ms) anti-Ms IgG Alexa 488 Blocking Solution 1 × PBS Nuclei solution
NeuN 1.2 μl 1 μl 100 μl 300 μl 1000 μl
Negative control 0 μl 0.2 μl 20 μl 60 μl 200 μlBMC Neuroscience 2008, 9:42 http://www.biomedcentral.com/1471-2202/9/42
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ing" of antibodies and other reagents. Therefore, pelleting
was important, but the challenge thereby was that post-
FACS nuclei became fragile and most of them were
destroyed by centrifugation in 1 × PBS. Therefore, we
tested different buffers and noticed that the presence of
Ca2+ and Mg2+ is crucial for integrity of nuclei during pel-
leting. Hence, the concentration of sucrose, Ca2+, and
Mg2+ in post-FACS nuclei solution was adjusted by adding
the following to each 10 mL of post-FACS nuclei: 2 mL of
1.8 M Sucrose, 50 µl of 1 M CaCl2, and 30 µl of 1 M
Mg(Ac)2. Samples were mixed gently, incubated on ice for
15 min, and centrifuged at 3000 rpm for 15 min at 4°C.
Chromatin immunoprecipitation
The FACS sorted nuclei were prepared either by micrococ-
cal nuclease digestion for native chromatin immunopre-
cipitation (NChIP) as described [37], or in case of fixed
nuclei, sheared by sonication (Branson Sonifier 250) for
XChIP. (Typically, samples were sonicated at power level
6 (Branson, Danbury CT) in ice water, by applying 10 runs
of 30 sec impulse with 1 min resting interval. Again, son-
ication conditions need to be optimized before each
experiment.) In the work presented here, only NChIP was
used. In brief, micrococcal nuclease (MNase) digestion
was performed with a working concentration of 4U/mL at
37°C for 5 min. The resulting mono-nucleosomal prepa-
ration (around 146 bp) [see Additional file 1, panel A]
was precleaned by incubating with protein G agarose
(which should also remove the antibodies used for NeuN
labeling of nuclei) and then subjected to immunoprecip-
itation using antihistone antibodies (see Reagents). Con-
trol experiments included samples processed with normal
rabbit IgG, in parallel to samples with specific antibodies.
Typically, we used 0.5 – 8 × 106 nuclei as input.
Real time PCR
Quantification of DNA extracted from immunoprecipi-
tates was done by real time PCR using custom-designed
primers targeting the promoter regions of the following
genes: (mouse) methyl CpG binding protein 2 (Mecp2),
glutamate decarboxylase 1 (Gad 1), ?2-microglobulin
(B2m), and Glial fibrillary acidic protein (Gfap); (human)
glutamate receptor, ionotropic, N-methyl D-aspartate 2B
(GRIN2B), brain derived neurotrophic factor (BDNF), ?2-
microglobulin (B2M), and the locus control region of the
globin genes (HBB). MouseMecp2 primer sequence (119
bp): forward GCCTCTTTTCCCTGCCTAAA, reverse
CCCTTGCTCTTTGTCGAGAT;  Gad 1 (98 bp): forward
TGTCTCACCAAAGTCCCTGTC, reverse CACGTCTGGT-
TCGGTGTCT;  B2m  (112 bp): forward GGGAAAGTC-
CCTTTGTAACCT, reverse GCGCGCGCTCTTATATAGTT;
Gfap  (100 bp): forward TACCAGAAAGGGGGTTCCTT,
reverse AACTCCTCTCACCCCACTGA. HumanGRIN2B
primer sequence (64): forward TCCTCTTCCATTCAG-
GTTGG, reverse GGCTATACCATTCCTGGGACA; BDNF
(102): forward AGCCCAACAACTTTCCCTTT, reverse
GAGAGCTCGGCTTACACAGG;  B2M  (99): forward
GGGCACCATTAGCAAGTCAC, reverse GGCGCTCAT-
TCTAGGACTTC; HBB (87): forward CCCCAGGTAGTTC-
CCTTT reverse TTCAAGGCCCTGTAGTTGCT.
Quantification was done as described [37]. For each of the
antibodies used in this study (anti-H3K4me2, -H3K9me3,
and -H3K4me3), specific signal was limited to input and
chip fractions, and differed from controls by at least 3–4
cycle thresholds [see Additional file 1, panel B, C].
ChIP-on-Chip
To study histone occupancy at gene promoters on a larger
scale, a mouse promoter array, M8K (Aviva Systems Biol-
ogy, San Diego, CA), containing 8000 40-mer oligonucle-
otide probes targeting gene promoters, was used. The
DNA samples were amplified and labeled by Aviva's
ChIP-GLAS system. Briefly, both input and immunopreci-
pated (ChIP) DNA were biotinylated and annealed to the
M8K-Oligo-Mix. The DNA samples were then amplified
by ligation mediated PCR with T3 and T7 based primers
(25 cycles), labeled with Atto 550 or 647, and hybridized
onto the chip. Amplification, labeling, hybridization, and
washing was carried out according to the manufacturer's
instruction (Aviva, AK-0524). Slides were scanned with
DNA Microarray ScannerBA (Agilent Technologies, Santa
Clara, CA, USA) and intensities extracted with Feature
Extraction Software Version 9.1 (Agilent Technologies,
Santa Clara, CA, USA). Raw data were read into the R sta-
tistical computation environment for preprocessing and
data analysis (R: Development core team (2004). R: A lan-
guage end environment for statistical computing. Vienna,
Austria.URL found in Availability and requirements sec-
tion). Local background intensities were subtracted from
raw signals and negative values were replaced with small
positive ones. Signals were then normalized using a vari-
ance stabilization method described in [38,39] and
implemented in the vsn Bioconductor package (Gentle-
man, RC. et. al., Bioconductor: open software develop-
ment for computational biology and bioinformatics.
Genome Biology 5, R80 (2004)).
Other amplification procedures
We used the Genomeplex whole genomic amplification
kit (WGA2, Sigma) to amplify DNA immunoprecipitates,
which resulted in 2 to 5 ug of (amplified) DNA from start-
ing material (10 ng of input DNA; ChIP DNA from 0.5 ×
106 nuclei).
Availability and requirements
R:A language end environment for statistical computing:
http://www.r-project.orgBMC Neuroscience 2008, 9:42 http://www.biomedcentral.com/1471-2202/9/42
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